Unraveling Psilocybin's Therapeutic Potential: Behavioral and Neuroplasticity Insights in Wistar-Kyoto and Wistar Male Rat Models of Treatment-resistant Depression

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2024 Jul 4

PMID 38963553

Authors

Magdalena Kolasa

Agnieszka Nikiforuk

Agata Korlatowicz

Joanna Solich

Agnieszka Potasiewicz

Marta Dziedzicka-Wasylewska

Ryszard Bugno

Adam Hogendorf

Andrzej Bojarski

Agata Faron-Gorecka

Affiliations

Soon will be listed here.

Abstract

Rationale: Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed light on the distinctive features of its antidepressant effects.

Objectives: We set out to assess the behavioral impact of acute and prolonged PSI administration on WKY and WIS rats, employing Novel Object Recognition (NORT), Social Interaction (SI), and Forced Swimming Test (FST). Our secondary objectives involved exploring strain-specific alterations in neuroplasticity-related parameters, including brain-derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton-associated protein (Arc).

Methods: Conducting post-acute and extended assessments after a single PSI administration, we applied behavioral tests and biochemical analyses to measure serum BDNF levels and neuroplasticity-related parameters in the prefrontal cortex. Statistical analyses were deployed to discern significant differences between the rat strains and assess the impact of PSI on behavioral and biochemical outcomes.

Results: Our findings uncovered significant behavioral disparities between WKY and WIS rats, indicating passive behavior and social withdrawal in the former. PSI demonstrated pronounced pro-social and antidepressant effects in both strains, each with its distinctive temporal trajectory. Notably, we identified strain-specific variations in BDNF-related signaling and observed the modulation of Arc expression in WKY rats.

Conclusions: Our study delineated mood-related behavioral nuances between WKY and WIS rat strains, underscoring the antidepressant and pro-social properties of PSI in both groups. The distinct temporal patterns of observed changes and the identified strain-specific neuroplasticity alterations provide valuable insights into the TRD phenotype and the mechanisms underpinning the efficacy of PSI.

Citing Articles

Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.

Rosas-Sanchez G, German-Ponciano L, Guillen-Ruiz G, Cueto-Escobedo J, Limon-Vazquez A, Rodriguez-Landa J Biomedicines. 2025; 12(12.

PMID: 39767650 PMC: 11727250. DOI: 10.3390/biomedicines12122744.

References

Abraham W, Logan B, Greenwood J, Dragunow M . Induction and experience-dependent consolidation of stable long-term potentiation lasting months in the hippocampus. J Neurosci. 2002; 22(21):9626-34. PMC: 6758050. View

Aleksandrova L, Wang Y, Phillips A . Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response. Neurosci Biobehav Rev. 2019; 105:1-23. DOI: 10.1016/j.neubiorev.2019.07.007. View

Antunes M, Biala G . The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2011; 13(2):93-110. PMC: 3332351. DOI: 10.1007/s10339-011-0430-z. View

Benekareddy M, Nair A, Dias B, Suri D, Autry A, Monteggia L . Induction of the plasticity-associated immediate early gene Arc by stress and hallucinogens: role of brain-derived neurotrophic factor. Int J Neuropsychopharmacol. 2012; 16(2):405-15. DOI: 10.1017/S1461145712000168. View

Bruzos-Cidon C, Miguelez C, Rodriguez J, Gutierrez-Lanza R, Ugedo L, Torrecilla M . Altered neuronal activity and differential sensitivity to acute antidepressants of locus coeruleus and dorsal raphe nucleus in Wistar Kyoto rats: a comparative study with Sprague Dawley and Wistar rats. Eur Neuropsychopharmacol. 2014; 24(7):1112-22. DOI: 10.1016/j.euroneuro.2014.02.007. View

Burke L, Heisler L . 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol. 2015; 27(6):389-98. DOI: 10.1111/jne.12287. View

Buzzelli V, Carbone E, Manduca A, Schiavi S, Feo A, Perederiy J . Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome. Psychopharmacology (Berl). 2022; 240(1):137-147. DOI: 10.1007/s00213-022-06286-3. View

Cameron L, Tombari R, Lu J, Pell A, Hurley Z, Ehinger Y . A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2020; 589(7842):474-479. PMC: 7874389. DOI: 10.1038/s41586-020-3008-z. View

Campus P, Colelli V, Orsini C, Sarra D, Cabib S . Evidence for the involvement of extinction-associated inhibitory learning in the forced swimming test. Behav Brain Res. 2014; 278:348-55. DOI: 10.1016/j.bbr.2014.10.009. View

10.

Carhart-Harris R, Erritzoe D, Williams T, Stone J, Reed L, Colasanti A . Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012; 109(6):2138-43. PMC: 3277566. DOI: 10.1073/pnas.1119598109. View

11.

Carhart-Harris R, Bolstridge M, Day C, Rucker J, Watts R, Erritzoe D . Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2017; 235(2):399-408. PMC: 5813086. DOI: 10.1007/s00213-017-4771-x. View

12.

Catlow B, Song S, Paredes D, Kirstein C, Sanchez-Ramos J . Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013; 228(4):481-91. DOI: 10.1007/s00221-013-3579-0. View

13.

Cavaleri D, Moretti F, Bartoccetti A, Mauro S, Crocamo C, Carra G . The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: Insight from meta-analyses. Neurosci Biobehav Rev. 2023; 149:105159. DOI: 10.1016/j.neubiorev.2023.105159. View

14.

Chan S, Harmer C, Norbury R, OSullivan U, Goodwin G, Portella M . Hippocampal volume in vulnerability and resilience to depression. J Affect Disord. 2015; 189:199-202. DOI: 10.1016/j.jad.2015.09.021. View

15.

Commons K, Cholanians A, Babb J, Ehlinger D . The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior. ACS Chem Neurosci. 2017; 8(5):955-960. PMC: 5518600. DOI: 10.1021/acschemneuro.7b00042. View

16.

de Azevedo Cardoso T, Mondin T, Wiener C, Marques M, Fucolo B, Pinheiro R . Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res. 2014; 39(8):1571-8. DOI: 10.1007/s11064-014-1349-4. View

17.

de la Fuente Revenga M, Zhu B, Guevara C, Naler L, Saunders J, Zhou Z . Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021; 37(3):109836. PMC: 8582597. DOI: 10.1016/j.celrep.2021.109836. View

18.

Dos Santos R, Osorio F, Crippa J, Riba J, Zuardi A, Hallak J . Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016; 6(3):193-213. PMC: 4910400. DOI: 10.1177/2045125316638008. View

19.

Doss M, Povazan M, Rosenberg M, Sepeda N, Davis A, Finan P . Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021; 11(1):574. PMC: 8575795. DOI: 10.1038/s41398-021-01706-y. View

20.

Drevets W, Price J, Furey M . Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008; 213(1-2):93-118. PMC: 2522333. DOI: 10.1007/s00429-008-0189-x. View